Insulet History: Founding, Growth & Key Milestones

The inspiration for Insulet arose in 2000 when entrepreneur John Brooks's young son was diagnosed with type 1 diabetes. Confronted with the agonizing daily routine of multiple daily fingerstick injections and the physical limitations of existing insulin pumps—which tethered children to pagersized pumps with three feet of snag-prone plastic tubing—Brooks resolved to engineer a radically better alternative. Partnering with medical device executive Duane DeSisto in Acton, Massachusetts, Brooks founded Insulet to create a miniature, disposable, tubeless insulin pump controlled wirelessly by a handheld remote. Developing the complex micro-fluidic pumping mechanism, biocompatible adhesives, automated needle inserter, and RF communications into a 25-gram waterproof pod required five years of intense engineering and multi-million-dollar venture funding. In 2005, Insulet achieved FDA 510(k) clearance for the first-generation Omnipod System, officially launching commercial sales in the US in 2006. Insulet completed its initial public offering on NASDAQ in 2007. The company's decisive breakthrough came with the launch of Omnipod DASH in 2018 and the historic FDA clearance of Omnipod 5 in 2022—the first tubeless automated insulin delivery system with full smartphone compatibility—propelling Insulet into a multibillion-dollar global market leader. In the decades following its initial founding, Insulet navigated rapid industry evolutions, transitioning from early legacy operating paradigms to modern integrated operations. This sustained focus allowed the company to survive cyclical macroeconomic contractions, outpace regional incumbents, and establish deep institutional trust with demanding stakeholders. Through disciplined capital allocation, continuous internal innovation, and targeted strategic initiatives, Insulet built an enduring competitive moat anchored by proprietary technology, deep domain expertise, and sticky relationships that resist structural disruption.